Immunotherapy / PD-1 inhibitorPhase 3 trialInvestigational
Tislelizumab
How it works
Tislelizumab blocks the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells.
Cancer types
Colorectal Cancer— All patients
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Fruquintinib and Tislelizumab in Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Combination Therapy Shows Promise for Rare Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 55.17% (95% CI, 35.69% - 73.55%). | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Melanoma | phase-1 | — | Source → |
| Testing Tislelizumab in Combination for Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Tislelizumab plus chemotherapy improves survival in advanced lung cancer | Lung Cancer | phase-3 | Median overall survival was 26.1 months in patients who received tislelizumab plus paclitaxel/carboplatin. | Source → |
| Rectal Cancer Trial Testing Chemotherapy, Radiation, and Immunotherapy | Colorectal Cancer | phase-2 | — | Source → |
| Tislelizumab Shows Promise in Lung Cancer Treatment | Lung Cancer | phase-3 | Tislelizumab significantly improved overall survival (hazard ratios: 0.72, 95% CI: 0.63-0.81) and progression-free survival (hazard ratios: 0.61, 95% CI: 0.54-0.68) compared to control treatments. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.